QIAGEN powered by
QCI Interpret preconfigured for TruSight™ Oncology 500

A streamlined workflow
from FASTQ to final report

Analyze with Precision. Interpret with Confidence.

A comprehensive answer
for cancer

As our molecular knowledge of cancer continually evolves, a new era in cancer care is beginning: comprehensive genomic profiling (CGP). With a single CGP test, we can map an individual’s unique genomic profile across all 4 types of alterations known to drive cancer growth. Capable of interrogating hundreds of genes, CGP provides deeper insight to help oncologists determine the best possible treatment for each patient and chart a treatment journey to identify courses of action should the disease progress. Now, the question is how to perform CGP faster.

Deeper insights. Faster results.

QCI Interpret for Oncology is an informatics platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale.

For labs using the Illumina® TruSight Oncology 500 assay, QCI Interpret offers a preconfigured, FASTQ to final report workflow that can detect single nucleotide variants (SNVs), indels, gene fusions, RNA splice variants, copy number variants (CNVs), tumor mutational burden (TMB), and microsatellite instability (MSI).

Significantly improving productivity and test turnaround time, QCI Intepret’s preconfigured workflow for TruSight Oncology 500 helps molecular diagnostic labs deliver actionable reports with speed, consistency, and confidence. 

Compare your current TruSight Oncology 500 report content with QCI Interpret’s

For a limited time, we are offering users of the TruSight Oncology 500 assay the opportunity to compare your current report content with the report content of QCI Interpret.

Over 3 million patient cases interpreted

Trusted by labs around the world, QCI Interpret for Oncology processes over 15,000 cases each month. To date, the software’s knowledge base has been used to interpret over 3 million patient cases.

Built over  25 years and updated weekly, the QIAGEN Knowledge Base leverages machine learning to rapidly index journal articles for mutations and human judgment and expertise (augmented molecular intelligence) to ensure accuracy, relevance and context—every catalogued “finding” has been “touched” by a trained scientist.

The world's fastest growing knowledge base

The content core of QCI Interpret for Oncology, the QIAGEN Knowledge Base is the world’s largest and
fastest growing collection of globally trusted molecular knowledge.

Precise Variants Characterized
QCI Interpret for Oncology contains over 6.4 million precise variants characterized in 18,000 genes.
New Variants Added Each Year
With over 5,000 new variants added each month, QCI Interpret for Oncology adds over 60,000 new variants per year.
Cases Processed Each Month
Trusted by labs around the world, QCI Interpret for Oncology processes over 15,000 cases each month.

FASTQ to report within minutes—not hours

QCI Interpret for Oncology’s preconfigured workflow for the Illumina TruSight Oncology 500 assay enables users to go from FASTQ to a precision NGS report through an automated and streamlined workflow to further accelerate turnaround times.

While offering preconfigured workflows for the Illumina TruSight Oncology 500 assay, QCI Secondary Analysis and QCI Interpret are panel- and workflow-agnostic and can utilize data from any sequencer.

For labs using an Illumina® sequencer and Illumina BaseSpace®, raw FASTQ sequencing files can be directly uploaded to QCI Secondary Analysis. For labs using other sequencers, a bulk file uploader tool can be used to upload data to QCI Secondary Analysis.

Once data has been uploaded to QCI Secondary Analysis, users then select a pre-configured analysis pipeline that has been optimized for their lab’s specific panel, policies, and standard operating procedures (SOPs).  Users also have the option to run and deploy any bioinformatics tools, such as QIAGEN’s CLC Genomics Workbench, within QCI Secondary Analysis.

QCI Secondary Analysis automates the analysis of multiple sequencing runs simultaneously, generating high-quality variant calls within minutes. Users can then visualize the analysis results, such as read pileups, in a genome browser directly from the cloud platform. Or, users can send VCF files directly to QCI Interpret, or download the results to send to the interpretation platform of their choice.

QCI Secondary Analysis seamlessly integrates with QCI Interpret, QIAGEN’s platform for NGS variant interpretation and reporting, via QCI Connect, a secure, cloud-based application.

Through a preconfigured workflow for TruSight Oncology 500, QCI Interpret dynamically computes pathogenicity and actionability based on the AMP/ASCO/CAP or ACMG/AMP guidelines for every variant in over 31,000 cancer types with full transparency. To simplify and accelerate interpretation, users have access to over 320,000 preformulated, oncologist-reviewed variant impact summaries to build custom, patient-specific reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and clinical trials.


Unique capabilities for TruSight Oncology 500

Enabling rapid comprehensive genomic profiling

With QCI Interpret for Oncology, you can be confident that every report you deliver is backed by the latest peer-reviewed publications, clinical practice guidelines, FDA therapeutics, and open clinical trials, all vetted by M.D. and Ph.D.-level expert curators who do the reading for you.

Via a dropdown menu, select a preconfigured TruSight Oncology 500 workflow and create a new test.

Seamlessly upload TruSight 500 Oncology data in a single step via a preconfigured workflow.

Use QCI Interpret for Oncology to group, filter, and prioritize genetic variants from the variant lists. Find actionable mutations in driver genes and match driver alterations with specific drugs allowing personalized therapeutic management. Sort your variants by interpretation type, alteration type, and clinical actionability in search for those that could be used as prognostic and therapeutic biomarkers.  

Clinical cases are deeply curated to gather specific evidence for automated computation of an AMP-recommended classification into 4 categories: Tier 1- variants of strong clinical significance (Level of evidence A and B), Tier 2- Variants of potential clinical significance (Level of evidence C and D), Tier 3 –Variants of unknown clinical significance, and Tier 4- Benign or Likely benign variants. For each computed classification the criteria engaged are displayed along with the supporting evidence.

In addition, QCI Interpret provides access to over 320,000 molecular function summaries and pre-written, oncologist- reviewed variant interpretive comments for faster report building.

Generate genomic reports with deeper insight

With QCI Interpret, you can easily generate a final report with only the most relevant findings. While labs can customize the layout to fit branding and reporting needs, standard reports include:

  • A summary of the high-level results, including biomarker findings and clinically relevant co-occurring variants.
  • Individual variant interpretations, including AMP/ASCO/CAP classifications, biomarker summaries, disease summaries, details on molecular function and incidence, and diagnostic and prognostic significance with region-specific clinical trials and approved drugs (FDA, EMA, PMDA) for each patient.
  • A bibliography containing all evidence considered in the final report.

Comprehensive genomic profiling of rare tumors

Rare cancer variants are difficult to identify and interpret due to limited knowledge on their biological and clinical significance. In this application note, experts share a comprehensive genomic profiling workflow using the TruSight Oncology 500 assay and QCI Interpret to detect and analyze rare cancer variants.

Customer testimonials
Christer Ericcson, PhD
Christer Ericcson, PhD Chief Scientific Officer, iCellate Medical AB
Read More
“Current and future cancer patients, and the healthcare systems, need the fastest possible responsible realization of the promise of personalized cancer medicine. iCellate’s implementation of novel biologically based cancer sample types and cancer tests are empowered by interfacing with QIAGEN’s powerful clinical decision support software QIAGEN Clinical Insight (QCI) Interpret.”
Miguel Ángel Molina Vila, PhD
Miguel Ángel Molina Vila, PhDTechnical Director, Laboratory of Oncology, Hospital Quirón Dexeus, Pangaea Oncology
Read More
“The Molecular Oncology lab needs to deliver reliable patient reports, clearly identifying clinically relevant genetic alterations. QCI Interpret is an invaluable tool to achieve this aim.”
Hiroyuki Mano, MD, PhD
Hiroyuki Mano, MD, PhDDirector of C-CAT, National Cancer Center of Japan
Read More
"The Center for Cancer Genomics and Advanced Therapeutics (C-CAT) and our network of hospitals will use the QCI solution because of the breadth and depth of its professionally curated knowledge base, the ability to match patients with approved treatments or clinical trials and QIAGEN’s customization of its QCI solution for C-CAT’s specific needs."
Stan Letovsky, PhD
Stan Letovsky, PhDVice President of Data Sciences and Bioinformatics, LabCorp
Read More
"Pairing [HGMD Professional] with QIAGEN's automated and scalable informatics framework facilitates our day-to-day secondary and tertiary bioinformatics analyses, and will help improve the quality of care for patients."
Contact us

See the content we
have for your variants

Want to see what content QCI Interpret can provide for your variants? Please complete the form below and our experts will show you the depth of content that our software provides.

Related NGS testing solutions

QCI Secondary Analysis
QCI Interpret for Oncology